Is the price fair?
What HROW's price assumes
Harrow, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 4.89× revenue.
4.89
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.89%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- +29%
Growth the price implies · The price pays for +29% free cash flow growth a year for a decade; revenue has grown +43% a year over the last three.
- Price / book
- 45.7
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 45.7
- EV / EBIT2026-Q1
- 77.2
- EV / sales2026-Q1
- 5.65
- Free cash flow, trailing twelve months
- $14M
- Market capitalisation
- $1.60B
- 3-year revenue growth
- +43%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #26 of 28 by Smart Score